公开(公告)号：US11795457B2

公开(公告)日：2023-10-24

申请号：US17486136

申请日：2021-09-27

Applicant: The Board of Regents of The University of Texas System

Inventor： David Corey ,  Liande Li

IPC: C07H21/04 ,  C12N15/113 ,  A61P25/00 ,  A61K45/06

CPC classification number: C12N15/113 ,  A61K45/06 ,  A61P25/00 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/3231

Abstract: Described are compounds and methods useful for the treatment and investigation of Friedreich's Ataxia.

公开(公告)号：US20230322684A1

公开(公告)日：2023-10-12

申请号：US18207777

申请日：2023-06-09

Applicant: CASE WESTERN RESERVE UNIVERSITY ,  Board of Regents of the University of Texas System

Inventor： Sanford Markowitz ,  Yiyuan Yuan ,  Yongyou Zhang ,  Joseph Ready ,  Bin Hu

IPC: C07D235/18 ,  C07D239/74 ,  C07D241/42 ,  C12N9/04

CPC classification number: C07D235/18 ,  C07D239/74 ,  C07D241/42 ,  C12N9/0006 ,  A61K45/06

Abstract: Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors described herein.

公开(公告)号：US20230302138A1

公开(公告)日：2023-09-28

申请号：US18311616

申请日：2023-05-03

Applicant: ReCode Therapeutics, Inc. ,  The Board of Regents of The University of Texas System

Inventor： Mirko Hennig ,  Vladimir Kharitonov ,  Brandon A. Wustman ,  Jackson Eby ,  Rumpa Bhattacharjee ,  Daniel Siegwart

IPC: A61K47/54 ,  C12N15/113 ,  A61K47/10 ,  A61K47/28 ,  A61K9/00 ,  A61P11/00

CPC classification number: A61K47/543 ,  C12N15/113 ,  A61K47/544 ,  A61K47/10 ,  A61K47/28 ,  A61K9/0073 ,  A61P11/00

Abstract: Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell, a ciliated cell, or a secretory cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled to a lipid composition. The lipid composition can comprise an ionizable cationic lipid, a phospholipid, and a selective organ targeting lipid. Further described herein are high-potency dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

公开(公告)号：US20230301988A1

公开(公告)日：2023-09-28

申请号：US18023661

申请日：2021-08-26

Applicant: The Texas A&M University System ,  The Board of Regents of the University of Texas System

Inventor： Thomas D. Meek ,  Chien-Te Tseng ,  Aleksandra Drelich ,  Drake M. Mellott

IPC: A61K31/495 ,  A61P31/14 ,  G01N33/569

CPC classification number: A61K31/495 ,  A61P31/14 ,  G01N33/56983 ,  G01N2333/165

Abstract: Provided herein are pharmaceutical compositions including compounds having Formula I (I) in an effective amount to inhibit non-viral cysteine protease (e.g., mammalian cysteine protease, such as human cathepsin L), as well as methods of using thereof.

公开(公告)号：US20230235055A1

公开(公告)日：2023-07-27

申请号：US18007185

申请日：2021-07-26

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Zhiqiang AN ,  Chengcheng ZHANG ,  Ningyan ZHANG ,  Yuanzhi CHEN ,  Heyu CHEN

IPC: C07K16/28 ,  A61K45/06 ,  G01N33/574 ,  A61K39/395 ,  A61P35/00

CPC classification number: C07K16/2803 ,  A61K45/06 ,  G01N33/57484 ,  A61K39/3955 ,  A61P35/00 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/73 ,  A61K2039/505

Abstract: Provided herein are antibodies binding to LILRB1 and the uses of the antibodies in detecting and treating cancer and autoimmune diseases.

公开(公告)号：US11690545B2

公开(公告)日：2023-07-04

申请号：US16357990

申请日：2019-03-19

Applicant: The Board of Regents of the University of Texas System

Inventor： Christopher John Zahner

IPC: A61B5/15 ,  B01F13/00 ,  B01F11/00 ,  B01L3/00 ,  A61J1/05 ,  B01F31/60 ,  B01F33/301 ,  B01F101/23

CPC classification number: A61B5/150755 ,  A61B5/150022 ,  A61B5/150206 ,  A61B5/150343 ,  A61J1/05 ,  B01F31/60 ,  B01F33/3017 ,  B01L3/00 ,  B01F2101/23

Abstract: In one embodiment, a mixing device includes a sleeve that forms an inner space configured to receive a sample container, a housing associated with the sleeve, a mixing element contained within the housing that is configured to mix liquid contained within the sample container, and an activation element configured to activate the mixing element when the activation element is triggered.

公开(公告)号：US11677071B2

公开(公告)日：2023-06-13

申请号：US16847909

申请日：2020-04-14

Applicant: National Technology & Engineering Solutions of Sandia, LLC ,  The Board of Regents of the University of Texas System

Inventor： Nelson S. Bell ,  Nancy A. Missert ,  Karen Lozano ,  Yatinkumar N. Rane

IPC: H01M4/04 ,  H01M4/131 ,  H01M4/13 ,  H01M4/505 ,  H01M4/525 ,  H01M4/36 ,  H01M4/1391 ,  H01M10/052 ,  H01M4/139 ,  H01M4/02

CPC classification number: H01M4/366 ,  H01M4/04 ,  H01M4/0471 ,  H01M4/13 ,  H01M4/131 ,  H01M4/139 ,  H01M4/1391 ,  H01M4/505 ,  H01M4/525 ,  H01M10/052 ,  H01M2004/021 ,  H01M2004/028

Abstract: A novel lithium battery cathode, a lithium ion battery using the same and processes and preparation thereof are disclosed. The battery cathode is formed by force spinning. Fiber spinning allows for the formation of core-shell materials using material chemistries that would be incompatible with prior spinning techniques. A fiber spinning apparatus for forming a coated fiber and a method of forming a coated fiber are also disclosed.

公开(公告)号：US11666634B2

公开(公告)日：2023-06-06

申请号：US16858557

申请日：2020-04-24

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： William T. Phillips

IPC: A61K38/22 ,  C07K14/575 ,  A61K38/00 ,  A61P3/08 ,  A61P3/10 ,  A61P1/00 ,  A61K49/18 ,  A61K49/10

CPC classification number: A61K38/22 ,  A61K49/10 ,  A61K49/1815 ,  A61P1/00

Abstract: Described herein are methods of management of functional dyspepsia in a patient by administering an amylin analogue or a CCK composition to the patient. Methods of diagnosing such patient include a standard gastric-emptying assessment using a standardized solid meal along with measurements of blood glucose levels. Another method of diagnosing such patient includes a gastric-emptying scintigraphy assessment with labeled carbohydrates or other assessments to diagnose rapid carbohydrate gastric emptying.

公开(公告)号：US20230165887A1

公开(公告)日：2023-06-01

申请号：US17934169

申请日：2022-09-21

Applicant: Astrocyte Pharmaceuticals, Inc. ,  The Board of Regents of the University of Texas System

Inventor： William S. KORINEK ,  James D. LECHLEITER ,  Theodore E. LISTON

IPC: A61K31/7076 ,  A61K31/52 ,  A61P25/00

CPC classification number: A61K31/7076 ,  A61K31/52 ,  A61P25/00

Abstract: The present invention relates to compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.

公开(公告)号：US20230149295A1

公开(公告)日：2023-05-18

申请号：US17906027

申请日：2021-03-09

Applicant: University of Houston System ,  The Board of Regents of The University of Texas System ,  Tract Pharmaceuticals, Inc.

Inventor： Frank McKEON ,  Rahul NEUPANE ,  Jingzhong XIE ,  Wa XIAN ,  Matthew VINCENT ,  Shan WANG

IPC: A61K9/00 ,  A61K47/34 ,  A61K45/06

CPC classification number: A61K9/0024 ,  A61K47/34 ,  A61K45/06

Abstract: The present disclosure addresses IBD from the standpoint of inhibiting or ablating pathogenic mucosal stem cells cloned from defined regions of disease in the gastrointestinal tract. In the case of Crohn's disease, for example, isolation of those stem cells according to the methods of the present disclosure reveals a pattern of inflammatory gene expression in stem cells from the terminal ileum and colon that is epigenetically maintained despite months of continuous cultivation in the absence of immune or stromal cells, or of intestinal microbes. Superimposed on this distributed inflammatory phenotype is a differentiation defect that profoundly and specifically alters the mucosal barrier properties of the terminal ileum. The co-existence of diseased and normal stem cells within the same endoscopic biopsies of Crohn's disease patients implicates an epigenetically enforced heterogeneity among mucosal stem cells in the dynamics of this condition.